Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company’s ambitions for a successor to its Wegovy weight-loss drug that is more powerful than Eli Lilly’s rival Zepbound, also known as Mounjaro.Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a ...

Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's weight loss drug CagriSema missed expectations of a late-stage study. The popularization of treatments such as Novo Nordisk's Ozempic, as well as Eli Lilly's (LLY) Zepbound for weight management caused quite the industry stir this year, with telehealth name Hims & Hers Health (HIMS) also joining the race.NVO is on track for its biggest daily and weekly percentage losses on record, as well as ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!As I'm writing these lines, Novo Nordisk A/S ( NVO ) is down about 16% on the pre-market session after the news came out that its obesity drug — CagriSema — delivered disappointing trial results, as Bloomberg reported an hourDaniel Sereda is chief investment analyst ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Key TakeawaysNovo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their body weight on average, below the company's reported goal of 25%, per Bloomberg.The drug combines semaglutide, the active ingredient in Ozempic and Wegovy, with another ingredient meant to reduce hunger and make patients feel full for longer. Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket tradi ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% on Friday, putting it on course for its worst-ever daily loss, after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations.The maker of the wildly popular Wegovy obesity drug said its new drug candidate helped patients reduce their weight by 22.7%, below the 25% it had forecast, according to Reuters.The s ...

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one o ...

Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic targetTotal potential deal value up to $186M in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales WALTHAM, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced a multi-year collaborati ...

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.There may be a new, unintended side effect linked to Novo Nordisk's blockbuster diabetes injection, Ozempic. Danish health authorities on Monday said they are asking the European Union's drug regulator to review the findings of two D ...